Skip to main content

Advertisement

SpringerLink
Log in

A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose Studies indicate that recombinant human endostatin (rh-endostatin) can inhibit tumor endothelial cell proliferation, angiogenesis, and tumor growth. This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with non-small-cell lung cancer (NSCLC). Patients and Methods Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m2 of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. The primary end point was objective response rate (ORR). Results Baseline characteristics were similar between treatment arms. The best ORRs for rh-endostatin arm (n = 33) and chemotherapy-alone arm were 37.5% (95% CI: 21.3 to 47.2%) and 28.6% (95% CI: 19.8 to 37.6%), respectively. Median survival was 12.4 months in the rh-endostatin arm and 9.8 months in the chemotherapy-alone arm, and 1-year survival was 51.6% and 38.7%, respectively. Mild palpitions, diarrhea, and liver dysfunction were the most common rh-endostatin-related adverse events. Grade 3/4 hematological toxicities were all reported similar for patients in the two arms. Conclusion The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Ardizzoni A, Boni L, Tiseo M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847–857

    Article  PubMed  CAS  Google Scholar 

  3. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  4. Italiano JE Jr, Richardson JL, Patel-Hett S et al (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet granules and differentially released. Blood 111:1227–1233

    Article  PubMed  CAS  Google Scholar 

  5. Tosetti F, Ferrari N, De Flora S et al (2002) ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16:2–14

    Article  PubMed  CAS  Google Scholar 

  6. Boehle AS, Kurdow R, Schulze M et al (2001) Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 94:420–428

    Article  PubMed  CAS  Google Scholar 

  7. Iizasa T, Chang H, Suzuki M, et al (2005) Expression of collagen XVIII in non-small cell lung carcinoma and its prognostic value. AACR Meeting Abstracts, 944

  8. Ni Q, Ji H, Zhao Z et al (2009) Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol 614:1–6

    Article  PubMed  CAS  Google Scholar 

  9. Sun Y, Wang J, Liu Y, et al (2005) Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. ASCO Meeting Abstracts :7138

  10. Han B, Xiu Q, Wang H, et al (2008) Rh-endostatin injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: randomized, double-blind, placebo-controlled, multicentre study. ASCO Meeting Abstracts :19126

  11. Le Chevalier T, Scagliotti G, Natale R et al (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80

    Article  PubMed  Google Scholar 

  12. Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E et al (2010) Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3463–3471

    Article  PubMed  CAS  Google Scholar 

  13. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  14. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  PubMed  CAS  Google Scholar 

  15. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL. J Clin Oncol 27:1227–1234

    Article  PubMed  CAS  Google Scholar 

  16. Lynch TJ, Patel T, Dreisbach L et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911–917

    Article  PubMed  CAS  Google Scholar 

  17. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 373:1525–1531

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank all the patients who chose to participate in this trial.

Author information

Authors and Affiliations

  1. The Department of Medical Oncology, Sichuan Cancer Hospital, No.55, Ren Min Nan Road, Chengdu, Sichuan, 610041, China

    Xin Zhao, Kai Mei, Xiaohong Cai, Jing Chen, Jingrui Yu & Chengya Zhou

  2. The Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China

    Qiu Li

Authors
  1. Xin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaohong Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jingrui Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chengya Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qiu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiu Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, X., Mei, K., Cai, X. et al. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs 30, 1144–1149 (2012). https://doi.org/10.1007/s10637-011-9631-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9631-7

Keywords

Search

Navigation